Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Incyte Corporation Trends and Insights

Biotech Giants' SG&A Expenses: A Decade of Growth and Strategy

__timestampIncyte CorporationNeurocrine Biosciences, Inc.
Wednesday, January 1, 201416577200017986000
Thursday, January 1, 201519661400032480000
Friday, January 1, 201630325100068081000
Sunday, January 1, 2017366406000169906000
Monday, January 1, 2018434407000248932000
Tuesday, January 1, 2019468711000354100000
Wednesday, January 1, 2020516922000433300000
Friday, January 1, 2021739560000583300000
Saturday, January 1, 20221002140000752700000
Sunday, January 1, 20231161300000887600000
Monday, January 1, 202412421570001007200000
Loading chart...

Cracking the code

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding financial trends is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Incyte Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Incyte's SG&A expenses surged by approximately 600%, peaking at $1.16 billion in 2023. In contrast, Neurocrine's expenses grew by nearly 4,800%, reaching $888 million in the same year.

Key Insights

  • 2014-2017: Incyte maintained a steady increase, while Neurocrine's expenses grew exponentially, reflecting aggressive expansion strategies.
  • 2018-2023: Both companies saw significant growth, with Incyte's expenses consistently outpacing Neurocrine's by about 30%.

These trends highlight the strategic financial decisions shaping the biotech landscape, offering investors a glimpse into each company's operational priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025